Mavupharma Inc., of Kirkland, Wash., said it secured $20 million in a series A financing led by Frazier Healthcare Partners and joined by Alpine Bioventures. Mavu is developing orally bioavailable, non-nucleotide modulators of the STING (stimulator of interferon genes) pathway to treat cancer and infectious diseases, and the funding will be used primarily to advance Mavu's lead drug candidates into the clinic.